Related Experiment Video
Updated: Aug 6, 2026
05:39
A Fine Motor Task to Study Joint Kinematics in a Preclinical Model of Neurodegenerative Disease
Published on: June 13, 2025
Amantadine Modulates Action-Specific Neural Ensembles in Hypokinetic and Hyperkinetic Conditions
Gaurav Chattree1,2, Radosław Chrapkiewicz2,3, Yanping Zhang2,4
1Department of Neurology and Neurological Sciences, Stanford University, Stanford, California, USA.
Summary
Amantadine improves motor function by modulating specific neural ensembles, not by rebalancing direct and indirect pathway spiny neurons. This suggests a distinct mechanism for treating hypokinetic and hyperkinetic movement disorders.
Area of Science:
- Neuroscience
- Movement Disorders
- Pharmacology
Background:
- Basal ganglia circuitry involves direct (dSPN) and indirect (iSPN) pathways regulating movement.
- Imbalances in dSPN/iSPN activity cause hypokinetic and hyperkinetic movement disorders.
- Amantadine's mechanism for improving both conditions is unclear.
Purpose of the Study:
- To investigate if amantadine normalizes dSPN/iSPN balance or acts via a different mechanism.
- To compare amantadine's effects with levodopa in Parkinson's disease models.
Main Methods:
- Dual-color two-photon Ca2+ imaging in a 6-hydroxydopamine (6-OHDA) mouse model.
- Monitoring dSPN and iSPN activity in hypokinetic and hyperkinetic states.
- Assessing action-specific neural ensemble activity.
Main Results:
- Levodopa normalized dSPN/iSPN imbalance but not locomotion ensembles in hypokinetic states.
- Amantadine improved locomotion ensembles without normalizing dSPN/iSPN balance.
- Amantadine suppressed dyskinesia ensembles in hyperkinetic states without affecting locomotion ensembles.
Conclusions:
- Levodopa normalizes pathway balance; amantadine modulates action-specific neural ensembles.
- Disruptions in action-coding ensembles are key in movement disorders.
- Targeting action-coding mechanisms offers a therapeutic strategy for motor dysfunction.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...